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PI3K/mTORC2 regulates TGF-b/Activin signalling
by modulating Smad2/3 activity via linker
phosphorylation
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Crosstalk between the phosphatidylinositol 3-kinase (PI3K) and the transforming growth
factor-b signalling pathways play an important role in regulating many cellular functions.
However, the molecular mechanisms underpinning this crosstalk remain unclear. Here,
we report that PI3K signalling antagonizes the Activin-induced deﬁnitive endoderm (DE)
differentiation of human embryonic stem cells by attenuating the duration of Smad2/3
activation via the mechanistic target of rapamycin complex 2 (mTORC2). Activation
of mTORC2 regulates the phosphorylation of the Smad2/3-T220/T179 linker residue
independent of Akt, CDK and Erk activity. This phosphorylation primes receptor-activated
Smad2/3 for recruitment of the E3 ubiquitin ligase Nedd4L, which in turn leads to their
degradation. Inhibition of PI3K/mTORC2 reduces this phosphorylation and increases the
duration of Smad2/3 activity, promoting a more robust mesendoderm and endoderm
differentiation. These ﬁndings present a new and direct crosstalk mechanism between these
two pathways in which mTORC2 functions as a novel and critical mediator.
DOI: 10.1038/ncomms8212 OPEN
1 Department of Surgery and Cancer, Institute of Reproductive and Developmental Biology, Imperial College London, Du Cane Road, London W12 0NN, UK.
w Present address: Department of Molecular Medicine, Faculty of Medicine, University of Malaya, 50603 Kuala Lumpur, Malaysia. Correspondence and
requests for materials should be addressed to W.C. (email: wei.cui@imperial.ac.uk).
NATURE COMMUNICATIONS | 6:7212 | DOI: 10.1038/ncomms8212 | www.nature.com/naturecommunications 1
& 2015 Macmillan Publishers Limited. All rights reserved.
C
ytokines of the transforming growth factor-b (TGF-b)
superfamily including Nodal and Activin, control many
cellular functions, such as cell growth, apoptosis and cell
fate determination. These functions are not only controlled by the
TGF-b pathway itself but are also extensively regulated by
crosstalk between TGF-b and other signalling pathways1–3.
TGF-b/Activin signalling is initiated upon ligand binding and
activation of receptor complexes, which leads to the phos-
phorylation of the Smad2 and Smad3 (henceforth Smad2/3)
C-terminal SxS motif, promoting their interaction with Smad4
and facilitating the translocation of the Smad2/3–Smad4
complexes to and accumulation within the nucleus where they
regulate targeted gene expression in cooperation with other
cofactors4–6. The efﬁcacy of this pathway is not solely determined
by the abundance of ligands and receptors but is also inﬂuenced
by other signalling pathways3. Notably, the phosphatidylinositol
3-kinase (PI3K) pathway has been shown to alleviate
TGF-b-induced apoptosis and cell cycle arrest in several
tumour cell lines7–10, as well as inhibiting the Activin-induced
DE differentiation of human embryonic stem cells (hESCs)11–13.
However, the molecular mechanisms behind these effects remain
contentious8–10. Although it has recently been proposed that the
negative effects of PI3K upon DE differentiation are an indirect
effect attributed to the inhibition of the Wnt-b-catenin
pathway14, it is unclear how this mechanism results in
enhanced Smad2/3 activity, thereby positing the existence of a
more direct relationship between these two pathways15.
In this study, we demonstrate that PI3K signalling has a direct
inhibitory effect on Activin-induced Smad2/3 activity in hESCs
via the activation of mechanistic target of rapamycin complex 2
(mTORC2), leading to a reduction of Smad2/3 transcriptional
activity and DE differentiation efﬁcacy. PI3K/mTORC2 nega-
tively regulates Smad2/3 activity by modulating their degradation
via phosphorylation of a particular threonine residue within the
Smad2/3 linker region. Our results therefore demonstrate a new
and novel mechanism underpinning the crosstalk between the
PI3K/mTOR and TGF-b/Activin signalling axes and in particular,
ﬁrmly establishes mTORC2 as a critical mediator in modulating
Smad2/3 activity.
Results
PI3K inhibits Activin-induced DE differentiation of hESCs. To
decipher the mechanisms underlying the antagonistic impact of
the PI3K pathway upon TGF-b/Activin activities and the DE
differentiation of hESCs, we developed a serum-free and chemi-
cally deﬁned culture condition to convert hESCs to DE, in which
high-dosage Activin A (henceforth AA) was shown to enhance
the activation of Smad2/3 signalling and DE differentiation as
previously reported (Supplementary Fig. 1a; Fig. 1a)11,12,16.
Under this culture condition, treatment of hESCs with
LY294002 (LY), a PI3K inhibitor, diminished Akt activation
even in the presence of AA (Fig. 1b). In comparison with the
differentiation using AA alone, co-treatment of hESCs with AA
and LY evidently enhanced the Activin-induced DE differen-
tiation as shown by a higher expression of mesendoderm and
DE markers (Fig. 1c–f). This LY-dependent enhancement of
DE differentiation was further corroborated by an increase in the
generation of functional hepatocyte-like cells and in multiple
hESC lines (Fig. 1g; Supplementary Fig. 1b,c). Therefore, this
chemically deﬁned culture system provides a useful platform
from which to further interrogate the underlying molecular
mechanisms driving the improvement of DE speciﬁcation.
Inhibiting PI3K prolongs Activin-induced Smad2/3 activation.
To interrogate the mechanisms through which PI3K signalling
interferes with TGF-b activities, we ﬁrst evaluated the activation
status of Smad2/3 under AA±LY conditions. Time-course ana-
lysis revealed that although LY treatment had no effect on the
initial activation of Smad2/3 (Smad2/3-pTail), the decline of
active Smad2/3 was clearly attenuated in AA–LY-treated cells
compared with cells treated with AA alone (Fig. 2a), resulting in a
marked increase of active Smad2/3 six hours post treatment
(Fig. 2b). AA–LY-treated cells also exhibited a signiﬁcant increase
in Smad2/3 transcriptional activity evidenced by higher luciferase
reporter activity (Fig. 2c) and a considerable upregulation of
mesendoderm markers MixL1, Eomes and goosecoid and DE
marker Sox17, which are known Smad2/3 targets (Fig. 2d)1,17,18.
This ﬁnding implies preferential speciﬁcation of the cells towards
the mesendoderm and DE even at this early stage of
differentiation. Furthermore, to rule out the possibility that
these enhancements were due to any off-target effects of LY, we
treated hESCs with two other PI3K inhibitors in the place of LY,
the more commonly used wortmannin and the more selective
Pictilisib (also known as GDC-0941). Both experiments largely
replicated the changes observed using AA–LY treatment
(Supplementary Fig. 2) Therefore, inhibition of PI3K directly
enhances Activin-induced DE formation by extending the
duration of Smad2/3 activity.
PI3K modulates ubiquitination and degradation of Smad2/3.
Since inhibition of PI3K extended the duration of Smad2/3
activation rather than altering their initial response to AA, we
reasoned that PI3K signalling might affect Smad2/3 activity
by regulating its turnover, either via phosphatase-mediated
dephosphorylation of the SxS motif or by ubiquitin-mediated
proteasomal degradation of the active Smad2/3 protein2. Until
recently, nuclear PPM1A was the only phosphatase identiﬁed to
dephosphorylate Smad2/3 at the SxS motif19, which is inhibited
by CLIC4 (chloride intracellular channel 4) protein20. However,
not only did LY treatment not affect the expression of either
protein, PPM1A was also detected primarily in the cytoplasm
(Supplementary Fig. 3a,b). It is therefore unlikely that Smad2/3
dephosphorylation by PPM1A is the mechanism accounting for
the phenotypic changes associated with AA–LY treatment.
Although one recent study has shown that PP5, a member of
the PPP phosphatase family, is able to dephosphorylate active
Smad2/3 upon overexpression21, treatment of hESCs with
okadaic acid, a potent inhibitor of PPP phosphatases, had no
effect on the decay kinetics of active Smad2 (Supplementary
Fig. 3c). Furthermore, enhanced TGF-b-induced transcriptional
responses that were observed in PP5-null mice has been shown to
result from increased levels of Smad3 protein rather than through
any direct effect upon the duration of their activation21.
These ﬁndings therefore further discount the involvement of
phosphatases in our underlying mechanism.
Given that ubiquitin-mediated proteasomal degradation is
another mechanism by which Smad2/3 activity is terminated22,
we next investigated whether LY acts to protect active Smad2
from proteasomal degradation. Similar decay kinetics for active
Smad2 was observed between LY- and MG132-treated cells, albeit
not with the same efﬁcacy (Fig. 3a–c). In addition, inhibition
of the Activin receptor by SB431542 did not abolish the effect of
LY, but rather made it observable much earlier at 1 h post
treatment (Fig. 3b). Together, this suggests that PI3K affects the
TGF-b/Activin pathway independent of receptor activity and acts
to promote the ubiquitin-mediated proteasomal degradation of
active Smad2/3. Although Nedd4L has been previously identiﬁed
as the ubiquitin ligase responsible for Smad2/3 ubiquitination23,
we observed no LY-dependent changes in its expression
(Supplementary Fig. 3d). However, LY treatment substantially
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reduced its interaction with Smad2 (Fig. 3d), which was
corroborated by decreased ubiquitination of Smad2 (Fig. 3e).
These results therefore highlight the critical role PI3K signalling
plays in regulating the association of Nedd4L with Smad2/3,
which in turn, dictates the duration and efﬁcacy of Smad2/3
activity.
PI3K primes Smad2/3 interaction with Nedd4L via pT220/T179.
Although activation of TGF-b/Activin signalling is primarily
determined by the receptor-mediated phosphorylation of
Smad2/3 C-terminal SxS motif that induces their accumulation
within the nucleus, it is increasingly apparent that the linker
region of Smad2/3 serves a critical site through which their
activity is regulated. This region contains multiple S/T residues,
which are targeted by various S/T kinases stemming from other
signalling pathways24–28. Phosphorylation of these residues
alters the interaction of Smad2/3 with other proteins, which
subsequently affects Smad2/3 stability, translocation and
transcriptional activity3,23,29,30. Recruitment of Nedd4L to
Smad2/3 was shown to be dependent on the phosphorylation
status of their linker T220/T179 residue, which lies directly
upstream of the PPXY-binding motif (Fig. 4a)23. Therefore,
we anticipated that PI3K signalling might affect Smad2/3
degradation through altering the phosphorylation of this
residue. Indeed, LY treatment signiﬁcantly reduced the
phosphorylation of T220/T179, irrespective of Smad2/3
activation, but had negligible effects on the other linker serine
residues in both hESC and tumour cell lines (Fig. 4b–d;
Supplementary Fig. 4a–e). This suggests that Smad2/3 linker
threonine and serine residues are differentially regulated,
with PI3K speciﬁcally modulating the phosphorylation of the
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Figure 1 | Inhibition of PI3K signalling promotes differentiation of hESCs to the deﬁnitive endoderm (DE). (a) Schematic illustrating the DE and
hepatocyte differentiation protocol. (b) H1 hESCs cultured in MEF-CM (CM) were transferred into deﬁned medium, RPMI/B27, for 1 h (time 0) prior to
treatment with Activin A±LY294002 (LY). Cell lysates were collected at indicated time points and analysed by immunoblot. (c) Gene expression analysis
by qRT–PCR in Activin A-treated hESCs with (red line) or without (blue line) LY. Data represent mean±s.d. from six measurements of two independent
differentiations. (d) Immunoblot showing mesendoderm marker expression in hESCs treated for 24 h with indicated factors. (e) Percentage of CXCR4-
positive cells by ﬂow cytometry in hESCs with or without indicated treatment for 3 days. Data represent mean±s.d. from three independent biological
samples. P value was calculated using the Student’s t-test. (f) Immunostaining with Brachyury and Sox17 antibodies in hESCs treated as indicated. Scale bar,
50mm. (g) hESCs were initially treated with Activin A±LY and then further differentiated to hepatocytes. Phase-contrast images (Phase-con) and
immunostaining with AFP and albumin antibodies are presented. Scale bar, 50mm.
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T220/T179 linker residue. Our results also demonstrate that
PI3K-mediated phosphorylation of this residue can occur in the
absence of Smad2/3 activation (Fig. 5a,d), which raised the
question as to whether Nedd4L binds to both active and inactive
Smad2/3 or solely to the active form. To address this, PC3 cells,
which retain high levels of PI3K signalling even after overnight
starvation due to the presence of a PTEN mutation, were used for
Nedd4L co-immunoprecipitation experiments upon treatment
with AA±LY post starvation. This showed that Nedd4L
recruitment and ubiquitination of Smad2/3 occurred most
effectively only when both T220/T179 and SxS residues were
phosphorylated (Fig. 4e), offering an explanatory mechanism
by which Nedd4L selectively targets active Smad2/3 for
ubiquitination and turnover.
We hence postulated that PI3K promotes phosphorylation of
Smad2/3-T220/T179 and primes Smad2/3 for the binding of
Nedd4L upon activation, resulting in increased ubiquitin-
mediated Smad2/3 degradation, which acts to reduce the
transcriptional activation of endoderm genes. If this is correct,
mutagenesis of T220/T179 to a non-phosphorylatable residue
should enhance the resistance of Smad2/3 to degradation
independent of LY. To test this, we ectopically expressed
wild-type (WT) or T220V mutant Smad2 in hESCs and PC3
cells. PC3 cells expressing Smad2-T220V showed higher Smad2/3
activation upon AA stimulation irrespective of whether LY
was present (Fig. 4f) and correspondingly, hESCs expressing
Smad2-T220V exhibited improved mesendoderm differentiation
in response to AA alone (Fig. 4g). In further support of the view
that Nedd4L-mediated degradation of active Smad2/3 accounts
for the inhibitory effect of PI3K during Activin-induced DE
differentiation, Nedd4L knockdown in PC3 cells resulted in
increased Smad2/3 activation in the absence of LY (Fig. 4h;
Supplementary Fig. 4f), while Nedd4L-deﬁcient hESCs expressed
endoderm genes at much higher levels upon AA stimulation
(Fig. 4i). Taken together, PI3K signalling therefore inhibits
Activin-induced DE differentiation by phosphorylating the
T220/T179 of Smad2/3, enabling the recruitment of Nedd4L
upon their activation, which leads to the degradation and
termination of active Smad2/3.
Smad2/3-pT220/pT179 is a direct effect of PI3K activity.
Although many kinases including Erk (extracellular-signal-
regulated kinases), p38 and CDK (cyclin-dependent kinase) have
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been shown to phosphorylate Smad2/3 linker residues24,26,27,30,
inhibitors that speciﬁcally target these kinases were less effective
in suppressing T220/T179 phosphorylation when compared
with LY (Fig. 5a,b; Supplementary Fig. 5a). Notably,
ﬂavopiridol-mediated inhibition of CDKs only diminished the
phosphorylation of the linker serine residues, whereas the
T220/T179 residue was unaffected. Furthermore, PI3K-mediated
phosphorylation of T220/T179 requires neither Smad2/3
activation nor nuclear localization, which thereby eliminates the
direct involvement of CDK in causing this effect. Although active
Erk can phosphorylate the T220/T179 residue, inhibition of PI3K
elicited a greater reduction in T220/T179 phosphorylation than
that of MAPK/Erk inhibition. In addition, LY treatment did not
inhibit, but rather increased Erk activation under certain
conditions (Fig. 5c; Supplementary Fig. 5a–c)14, which therefore
excludes the possibility of LY-induced downregulation of
T220/T179 phosphorylation being an Erk-related event.
Furthermore, treatment of hESCs in RPMI base media along
with heregulin and IGF-1 (HI), two potent stimulators of the
PI3K pathway, increased T220/T179 phosphorylation (Fig. 5d),
suggesting that this phosphorylation is regulated by the PI3K
pathway itself independent of Erk and CDK activity.
Since Akt is one of the principal kinases acting downstream
of PI3K, we next investigated whether Akt was responsible for
T220/T179 phosphorylation by ectopically expressing constitu-
tively active (Myr-Akt-WT), partially active (S473A) and inactive
(K179M/T308A/S473A) Akt in Hep3B cells, using green
ﬂuorescent protein (GFP)-expressing Hep3B as controls. In
comparison with the marked upregulation and reduction of
T220/T179 phosphorylation observed in control cells upon
heregulin and IGF-1 and LY treatment, respectively, expression
of Akt possessing varying states of activation had negligible
impact on T220/T179 phosphorylation (Fig. 5e), suggesting that
Akt is not directly responsible for this phosphorylation. This was
further conﬁrmed by an in vitro kinase assay that demonstrated
the inability of fully active Akt to phosphorylate this residue
(Fig. 5f), which is consistent with previous ﬁndings8–10.
mTORC2 induces the phosphorylation of Smad2/3-T220/T179.
The mTOR branches of the PI3K signalling pathway acts to
regulate cell growth, differentiation and metabolism. mTOR is the
kinase component of two distinct multi-protein complexes,
mTORC1 and mTORC2, which differ not only in their con-
stituent components, but also in their response to rapamycin31.
mTORC1 contains an adaptor protein, raptor, as a key subunit,
while mTORC2 comprises rictor as its novel component; while
mTORC1 activity is rapidly inhibited by rapamycin, mTORC2 is
more resistant to acute rapamycin exposure32. To investigate
whether mTOR complexes are involved in Smad2/3 regulation,
PC3 cells were treated with AA in the presence of rapamycin or
Torin-2 (henceforth Torin), an mTOR inhibitor that inhibits both
complexes. While rapamycin showed no obvious effects on both
Smad2 activation and T220/T179 phosphorylation (Fig. 6a),
Torin treatment mimicked that of LY in prolonging Smad2
activation and inhibiting T220/T179 phosphorylation (Fig. 6b),
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thereby suggesting that mTORC2, rather than mTORC1, is
involved in the regulation of Smad2/3 activity. In support of this
notion, phosphorylation of T220/T179 was shown to be
downregulated in rictor knockdown PC3 cells (Fig. 6c) and this
reduction of pT220/pT179 appeared more evident in MEFs
(mouse embryonic ﬁbroblasts) that were derived from rictor null
mice (Fig. 6d)33. The difference between rictor knockdown and
rictor null cells could be due to the incomplete removal of rictor
in the former as we have shown that PI3K/mTORC2-dependent
phosphorylation of T220/179 is highly sensitive to any trace
amount of PI3K/mTORC2 activity (Fig. 5d vs Supplementary
Fig. 5b). Furthermore, this downregulation of T220/T179
phosphorylation in rictor null cells was fully rescued by the
ectopic expression of human rictor (Fig. 6d), highlighting the
important role mTORC2 plays in regulating Smad2/3-T220/T179
phosphorylation. Moreover, hESCs expressing rictor short
hairpin RNA (shRNA) exhibited improved DE differentiation
in response to AA treatment evidenced by rapid morphological
changes and increased expression of DE markers, effects that are
reminiscent of those observed upon AA–LY treatment (Fig. 6e,f).
Therefore, these results suggest that mTORC2 plays an important
role in modulating Activin-induced Smad2/3 activity by
modifying the phosphorylation of the Smad2/3 linker
T220/T179 residue. Intriguingly, immunoprecipitated mTORC2
was unable to phosphorylate Smad2-T220 in an in vitro kinase
reaction (Fig. 6g), while inhibition of SGK1, one of the limited
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substrates identiﬁed to be regulated by mTORC2 (refs 34,35),
exhibited considerable reduction of both active and total Smad2/3
(Supplementary Fig. 6), effects that are completely different to
that of either LY treatment or mTORC2 inhibition. Thus,
the exact mechanisms by which mTORC2 regulates the
phosphorylation of Smad2/3 linker residue await further
elucidation.
Suppression of mTORC2 leads to more efﬁcient DE formation.
Consistent with the posited role for mTORC2 in regulating
T220/T179 phosphorylation and inhibiting Smad2/3 activity,
treatment of hESCs using a combination of AA and Torin yielded
a substantial increase in the expression of endoderm genes
(Fig. 7a,b), recapitulating the effects of AA–LY treatment, but
with noticeably less cell death. Consequently, this led to both a
more efﬁcient DE differentiation and hepatocyte generation
(Fig. 7c,d). Thus, the greater yield of DE cells in combination with
the reduction in cytotoxicity makes AA–Torin a superior alter-
native to AA–LY treatment and provides compelling evidence to
suggest that the mTORC2-mediated regulation of Smad2/3 linker
phosphorylation is a critical mechanism accounting for the
inhibitory effect of PI3K on Activin-induced DE differentiation.
Discussion
In the present study, we have identiﬁed a novel and direct role for
PI3K/mTORC2 signalling in regulating the phosphorylation
status of the Smad2/3 linker T220/T179 residue. This phos-
phorylation permits the recruitment of the E3 ubiquitin ligase
Nedd4L to Smad2/3 upon their activation, which subsequently
promotes the ubiquitin-mediated proteasomal degradation of
active Smad2/3. PI3K/mTORC2-mediated degradation of
active Smad2/3 curtails the duration and intensity of the
Activin-Smad2/3 signal, which ultimately leads to the attrition
of Activin-induced DE differentiation in hESCs.
Our results are in line with previous ﬁndings, in that ubiquitin-
mediated proteasomal degradation of active Smad2/3 plays an
important role in the regulation of TGF-b/Smad2/3 activity22,23
and that the phosphorylation of Smad2/3 linker T220/T179 is
critical for the recruitment of the E3 ubiquitin ligase Nedd4L23.
However, we have found that the T220/T179 residue can be
readily phosphorylated by PI3K/mTORC2 signalling in the
absence of Smad2/3 activation and is thus independent of
AA-induced CDK or Erk activation. Furthermore, this
phosphorylation can only recruit Nedd4L efﬁciently upon
Smad2/3 activation, thereby offering a mechanism by which
preferential selectivity for active Smad2/3 degradation is
established. In addition, TGF-b ligands are able to activate
PI3K signalling through non-canonical means concurrently with
the canonical activation of Smad2/3 (ref. 36), which may act as an
internal regulative mechanism that prevents overactivation of
Smad2/3. However, given that the majority of active Smad2/3 is
still able to translocate into the nucleus despite the presence of
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T220/T179 phosphorylation (Supplementary Fig. 4e), this
suggests that additional factors that interact with active
Smad2/3 may hinder the recruitment of Nedd4L and prevent
their degradation. Receptor-mediated activation of Smad2/3 has
been well characterized for inducing conformational changes that
enable the homo- and heterodimerization of R-Smads, as well as
interaction with Smad4. However, whether or not such
interactions between the Smad2/3 and other factors can act to
impede the recruitment of Nedd4L awaits further investigation.
In any case, despite only a small proportion of the activated
R-Smads being targeted for degradation, this appears to be
sufﬁcient in impeding the proper formation of DE from hESCs.
To deﬁnitively establish that Smad2/3 linker phosphorylation
mediates the mTORC2-dependent inhibition of DE differ-
entiation of hESCs, one would need to generate hESCs with
knock-ins of linker phospho-deﬁcient or phospho-mimetic
mutants of Smad2/3.
As shown in our experiments, AA–LY-induced enhancement
of Smad2/3 activation in hESCs is only apparent at 3 h post
treatment, despite the effectiveness of LY in reducing T220/T179
phosphorylation by 1 h of treatment. In explaining this
discrepancy, it is probable that initially in the presence of
abundant ligand (100 ngml 1 AA) and persistent receptor
activation37, the rate of Smad2/3 activation outpaces that of its
Nedd4L-mediated degradation, which consequently obscures
the effect of LY-induced downregulation of T220/T179
phosphorylation in prolonging Smad2/3 activation. However, as
the ligand availability diminishes with increasing time, the
proportion of the active Smad2/3 that is targeted for Nedd4L-
mediated degradation becomes increasingly higher relative to the
total active Smad2/3 pool, which ultimately promotes the rapid
downregulation of Smad2/3 activity (Fig. 8). In support of this,
the LY-dependent effect on active Smad2/3 was shown to be
evident at 1 h post treatment when a lower dose of ligand
(10 ngml 1 AA) is applied or when receptor activation is
blocked by SB431542. Putting this in a biological context, during
embryonic development where TGF-b/Nodal/Activin are
at physiological levels, this PI3K/mTOR/Nedd4L-mediated
degradation mechanism may act as an internal thermostat
that regulates the amplitude of Smad2/3 induction and
thereby allowing proper readout of the morphogenic gradient
in vivo.
One important ﬁnding of this study is the identiﬁcation of
mTORC2 as a modulator of TGF-b signalling, speciﬁcally by
regulating the phosphorylation of the Smad2/3 linker T220/T179
residue. In assessing the contribution of the previously identiﬁed
linker kinases, Erk1/2 and CDK24,26,27, we showed that when
inhibited, neither could replicate the effects of PI3K inhibition.
Furthermore, under certain conditions, LY-mediated inhibition
of PI3K did not reduce, but rather enhanced the activation of
Erk1/2. As such, enhancement of DE differentiation via
downregulation T220/T179 phosphorylation and enhancement
of Smad2/3 activity does not appear to be solely through an
Erk/Wnt/b-catenin-mediated mechanism as outlined in a recent
study14, but is rather through a more distinct and direct
mechanism. The PI3K pathway bifurcates at many points and
constitutes a large family of serine/threonine kinases of which the
best characterized are the Akt and mTOR branches. Our data
have shown that Akt does not affect phosphorylation of Smad2/3-
T220/T179, which is consistent with previous ﬁndings8–10. In
manipulating mTORC2 activity using both inhibitor-based and
genetic means, we have identiﬁed mTORC2 as a key player in the
regulation of the linker T220/T179 phosphorylation opposed to
mTORC1. Although it has been reported that inhibition of
mTORC1 by rapamycin can enhance the DE speciﬁcation of
hESCs38, chronic exposure of hESCs to rapamycin over several
days will also inhibit mTORC2 activity32, which may ultimately
be the reason for the reported improvement in DE speciﬁcation.
Furthermore, since mTORC2 activation is mediated by PI3K39, it
is not surprising that the inhibition of PI3K signalling could lead
to a cessation of mTORC2 kinase activity. Although mTORC2
immunoprecipitates could not phosphorylate the T220/T179
residue in an in vitro kinase reaction, this cannot completely
exclude the possibility of mTORC2 being the direct kinase
responsible for this phosphorylation, as the substrate recognition
mechanisms of mTORC2 are still poorly deﬁned39,40.
Alternatively, mTORC2 may indeed act via indirect means
through activation of downstream kinases that in turn regulate
Smad2/3 linker phosphorylation; however, such kinases remain to
be identiﬁed.
As a whole and to the best of our knowledge, we have for
the ﬁrst time identiﬁed a role for mTORC2 in mediating
TGF-b/Activin signalling activities, and established a plausible
mechanism through which mTORC2 activity directly impacts the
Activin-induced DE differentiation of hESCs. Identiﬁcation of
mTORC2 as a key component of this mechanism not only
provides new avenues through which hESC differentiation
protocols can be improved, but also warrants the initiation of
further studies into the impact of this mechanism on other
TGF-b activities, adding to the growing repertoire of novel
mTORC2 functions.
Methods
Cell culture and differentiation. H1 and H9 hESCs from WiCell were routinely
cultured on Matrigel-coated plates in MEF conditioned medium (MEF-CM)
supplemented with 10 ngml 1 of bFGF41. DE differentiation was carried out as
summarized in Fig. 1a12. When hESCs were grown to 70–80% conﬂuency,
MEF-CM was replaced with RPMI-1,640 supplemented with 1 B27 (RPMI/B27
medium) containing Activin (100 ngml 1, PeproTech) and LY294002 (20 mM
day 1 and 10mM day 2 and 3, Sigma) or Torin-2 (15 nM, Tocris) or wortmannin
(300 nM, Sigma) for 2–3 days with daily medium change (Supplementary Fig. 1b).
For hepatocyte differentiation, cells were further cultured in knockout-DMEM
(KO-DMEM) containing 20% KO serum replacement, 1mM glutamine,
1% non-essential amino acids, 0.1mM b-mercaptoethanol (all from Life
Technologies) with either DMSO (1%, Sigma) or BMP2 (20 ngml 1, PeproTech)
and bFGF (10 ngml 1, R&D systems) for another 4 days, followed by 3–5 days
culture in L15 medium supplemented with 8.3% foetal bovine serum (FBS),
8.3% tryptose phosphate broth, 10 mM hydrocortisone 21-hemisuccinate, 1 mM
insulin (all from Sigma), 50 mgml 1 ascorbic acid and 2mM glutamine containing
10 ngml 1 hepatocyte growth factor (PeproTech) and 20 ngml 1 oncostatin M
(R&D systems). In the experiments using various inhibitors, hESCs were cultured
in RPMI/B27 medium containing Activin (100 ngml 1) for 20min following
MEF-CM removal and 2 PBS wash (Fig. 3a). The Activin-containing medium
was then replaced with fresh RPMI/B27 containing the indicated inhibitors, and
cells were harvested 1–6 h later as indicated. The following inhibitors were used:
MG132 (10 mM) and okadaic acid (5 nM) from Merck/Millipore; SB431542
(10 mM) from Sigma; U0126 (10 mM) and SP600125 (500 nM) from Reagents
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Direct; SB203580 (20 mM) from R&D systems, ﬂavopiridol (1mM) and GDC-0941
(200 nM), both from Selleck Bio.
PC3 cells were kindly provided by Dr Kypta of Imperial College London.
Hep3B and HEK293T tumour cell lines were obtained from ATCC (HB8064 and
CRL-3216, respectively). Rictor null and corresponding control MEF were a gift
from Professor Magnuson, VUMC, Tennessee33. PC3 cells were cultured in RPMI-
1,640 medium containing 10% FBS. Hep3B, HEK293T and transgenic MEF cells
were cultured in DMEM containing 10% FBS. All reagents for tumour cell cultures
are from Sigma. Treatment of PC3 cells were performed by starving the cells
overnight in RPMI-1,640 medium and then treating them for 1 h with Activin
(10 ngml 1)±LY (20 mM) or indicated factors, including rapamycin (100 nM),
LongR3 IGF-1 (I, 200 ngml 1, both from Sigma), Heregulin (H, 10 ngml 1,
PeproTech) and SGK inhibitor, GSK650394 (100 mM, Sigma).
All cell lines have been regularly checked for the absence of mycoplasma.
Plasmids. Expression vectors for WT Smad2 (pCS2-Flag-Smad2, #14042), active
Akt (pcDNA3 Myr-HA-Akt1, #9008) Akt triple mutant (pcDNA3-T7-Akt-
K179M/T308A/S473A, #9031) and Rictor (pRK-myc-Rictor #11367) were obtained
from Professor J. Massague42, Professor W. Sellers43 and Professor D. Sabatini44
through Addgene. Smad2 mutant T220V was generated by site-directed
mutagenesis of pCS2-Flag-Smad2 using the Q5 Site-Directed Mutagenesis Kit
(NEB) following the manufacturer’s protocol, with the following oligonucleotides:
forward primer 50-GAGTAATTATATTCCAGAAGTGCCACCTCCTGGA
TATATC-30 and reverse primer 50-TGTGGCTCAATTCCTGCTGG-30 . The
resulting sequences were validated by bidirectional sequencing. Partially active Akt
(S473A) plasmid was generated by subcloning to replace the BlpI/EcoRI fragment
of pcDNA3-Myr-HA-Akt1 containing S473 with A473 from pcDNA3-T7-Akt1-
K179M/T308A/S473A. Lentivector containing shNedd4L was generated by cloning
shNedd4L oligonucleotides into modiﬁed pLVTHM expressing puro-2A-GFP
complementary DNA (cDNA)45. The sequence of shNedd4L was as previously
published23:
50-GCTAGACTGTGGATTGAGTttcaagagaACTCAATCCACAGTCTAGCtttttgg
aaa-30 . Lentivectors that contained two different shRNAs targeting Rictor within a
pLKO.1 backbone were obtained from Addgene and used in combination to
generate Rictor deﬁcient lines. The sequences are as previously published46:
50-ccggtCAGCCTTGAACTGTTTAActcgagTTAAACAGTTCAAGGCTGtttttg-30
and 50-ccggtACTTGTGAAGAATCGTATCTTctcgagAAGATACGATTCTTCACA
AGTtttttg-30 . Lentivectors containing non-targeting shGFP was used to generate
control cells. GST-Flag-Smad2/Smad2-T220V plasmids were generated by
inserting NcoI/XhoI fragment containing Flag-Smad2 or Flag-Smad2-T220V from
their respective expression vectors into the pGEX-6p2 vector (GE Healthcare).
Transfection and lentiviral transduction. Hep3B cells and transgenic MEFs were
grown to 70–90% conﬂuency on the day of transfection. Akt or GFP expression
plasmids were transfected using Lipofectamine LTX with PLUS reagent (Life
Technologies) with modiﬁcations. In brief, for 1 106 tumour cells, 1.6 mg of kit-
puriﬁed plasmid DNA was suspended in 50 ml of OptiMEM supplemented with
1.6 ml of PLUS reagent. In another tube, 4 ml of Lipofectamine LTX reagent was
resuspended in another 50 ml of OptiMEM. Both tubes were incubated at room
temperature for 5min before being mixed together and incubated for a further
25min. During this time, target cells were trypsinized, counted and pelleted before
being directly resuspended in the transfection mix and incubated for 15min. The
transfection process was stopped upon the addition of growth media and cells were
allowed to plate down overnight in the appropriate culture vessel. Cells were
typically split 1:2–1:3 following transfection. Reagents were scaled up accordingly
depending on the number of cells to be transfected. For hESCs and MEFs,
lipofection was conducted following the accompanying manufacturer’s instructions
with a DNA to Lipofectamine LTX ratio of 1:3 and 1:10, respectively. Transfected
Hep3B cells were starved overnight the following day and then treated with the
appropriate reagents for 1 h before being harvested for analysis. Transfected MEFs
were allowed to recover and proliferate for 48 h before being harvested for
immunoblot.
Lentiviruses were produced by transient transfection of HEK293T cells with a
lentivector containing the desired transgenic cDNA or shRNA, as well as
pCMVD8.91 helper and pVSV-G envelope plasmids using standard protocols47.
hESCs were split 1:3 the day of transduction by being dissociated with accutase
(Sigma) into single cells and resuspended in MEF-CM supplemented with 10 mM
ROCKi (Y-27632 or ROCK inhibitor, Reagents Direct) to prevent apoptosis
induced by the loss of cell–cell contact48. The cells were incubated overnight with
concentrated viral particles and consequently became infected as they were plating
down. Forty-eight hours post infection, cells were selected with puromycin
(2mgml 1) and upon stable passaging, assessed for transgene expression or
knockdown via immunoblot and quantitative reverse transcription (qRT–PCR),
which was phenotypically assessed via DE differentiation.
Quantitative reverse transcription–PCR (qRT–PCR). Total RNAs were isolated
from cells with TRI reagent (Sigma) and cDNA samples were synthesized with
Protoscript II Reverse Transcriptase (NEB). qRT–PCR was performed in a DNA
Engine Opticon (Bio-Rad) or Step One thermocycler (Applied BioSystems) using
SYBR Green Jumpstart Taq Ready Mix (Sigma). Two housekeeping genes were
used as normalizer. Two independent biological samples were used and multiple
measurements were carried out for each treatment. Data were presented as
mean±s.d. for six measurements. A list of primers used in this study are provided
in Supplementary Table 1.
Cytoplasmic/nuclear fractionation. Cells were harvested in cytoplasmic buffer
(10mM HEPES pH 7.9, 0.1mM EDTA, 0.1mM EGTA, 10mM KCl and 0.5mM
dithiothreitol (DTT)) supplemented with phosphatase and protease inhibitors and
allowed to swell on ice for 20min after which Nonidet-P40 was added to a ﬁnal
concentration of 0.5%. Samples were quickly vortexed and centrifuged to pellet the
cell nuclei. The supernatant was extracted and retained as the cytoplasmic fraction.
The nuclear pellet was washed three times with cytoplasmic buffer to remove
residual cytoplasmic contamination and resuspended in nuclear buffer (20mM
HEPES pH 7.9, 1mM EDTA, 1mM EGTA, 1mM DTT and 0.4M NaCl) before a
ﬁnal centrifugation at 15,000g to extract the nuclear fraction. Samples were
quantiﬁed using bicinchoninic acid assay kit (Thermo Fisher Scientiﬁc) before
being analysed by immunoblot.
Antibodies. The following are the primary antibodies used in this study; indicated
dilutions refer to use in immunoblotting, unless otherwise stated: anti-Akt (#9727,
1:2,000), pAkt-S473 (#4060, 1:2,000), pAkt-T308 (#9275, 1:1,000), Erk1/2 (#9102,
1:1,000), pErk1/2-T202/Y204 (#9106, 1:1,000), mTOR (#2972, 1:1,000), pNedd4L-
S448 (#8063, 1:1,000), P70S6K (#9202, 1:1,000), pP70S6K-T421/S424 (#9204,
1:1,000), pGSK3a/b-S21/9 (#9331, 1:1,000), pRb-S780 (#9307, 1:1,000), pSAPK/
JNK-T183/Y185 (#4668, 1:1,000), Smad2 (#3122, 1:1,000), Smad2/3 (#3102,
1:1,000), pSmad2-S245/250/255 (#3104, 1:1,000), pSmad2-S465/467 (#3122,
1:1,000), Smad4 (#9515, 1:1,000) and Ubiquitin (#3936, 1:1,000) were from Cell
Signalling/New England Biolabs; anti-Brachyury (AF2085, 1:500, IF:1:50), CXCR4-
PE (FAB170P, 1:25) and Sox17 (MAB1924, 1:500, IF:1:100) were from R&D sys-
tems; anti-CLIC4 (sc-130723, 1:500), Lamin B (sc-365962, 1:500) and PPM1A (sc-
56956, 1:500) were from Santa Cruz; anti-AFP (A8452, 1:500), b-actin (A5316,
1:5,000), Flag (F1804, 1:1,000) and GST (G7781, 1:1,000) were from Sigma; anti-
pSmad2/3-T220/179 (AP3675a, 1:500) and pSmad3-S423/425 (EP823Y, #04-1042,
1:1,000) were from Abgent and Millipore, respectively; anti-b-tubulin (ab6046,
1:1,000), FoxA2 (ab60721, 1:200) and Nedd4L (ab131167, 1:5,000) were from
Abcam; anti-albumin (A0001, 1:500) was from DAKO and anti-Rictor (A300-
459A, 1:5,000) was from Bethyl Labs.
Secondary antibodies for immunostaining used were as follows: Alexa Fluor
goat anti-mouse IgG 488, 1:400, Alexa Fluor goat anti-mouse IgG 568, 1:400, Alexa
Fluor goat anti-rabbit IgG 488, 1:400 and Alexa Fluor donkey anti-goat IgG 488,
1:400 were from Life Technologies. For immunoblotting: goat anti-rabbit
IgG-HRP, 1:2,000, goat anti-mouse IgG-HRP, 1:5,000, donkey anti-goat IgG-HRP,
1:5,000 were from Santa Cruz and goat anti-rabbit or mouse IgG-HRP (light-chain
speciﬁc), 1:10,000 were from Jackson ImmunoResearch Laboratories. Isotope
controls: normal mouse IgG2a and normal rabbit IgG were from Santa Cruz.
Immunostaining of hESCs. hESCs were split and cultured on Matrigel-coated
Thermanox coverslips (Thermo Fisher Scientiﬁc) until the desired conﬂuency was
reached. Cells were then washed with Dulbecco’s PBS (DPBS) and ﬁxed for
10–20min with 4% fresh paraformaldehyde solution. Excess paraformaldehyde was
removed by washing three times with DPBS and the coverslips were then incubated
with blocking/permeabilization buffer for 1 h followed by an overnight incubation
with primary antibody at the appropriate dilution at 4 C with tilting. The
following day, coverslips were subjected to 10-min washes three times with DPBS,
followed by a 40-min incubation with the appropriate ﬂuorophore-conjugated
secondary antibody in the dark. Coverslips were then subjected to two further 10
min washes with DPBS followed by a 10-min DPBS/40 ,6 diamidino-2-phenylindole
(DAPI) wash, with DAPI at a ﬁnal concentration of 1 mgml 1 to counterstain the
nuclei. All washes were carried out in dark. Slides were mounted onto microscope
slides using Mowiol 4–88 solution and allowed to dry overnight. Slides were
visualized using a Leica SP5 II confocal ﬂuorescent microscope typically at  64
magniﬁcation.
Immunoblotting. Cells were harvested using RIPA (radio immunoprecipitation
assay) buffer (50mM Tris-HCl, pH 8.0, 150mM NaCl, 1% Nonidet-P40, 0.5%
sodium deoxycholate and 0.5% SDS) supplemented with phosphatase (Na3VO4,
1:100, NaF, 1:200 or phosphatase inhibitor cocktail 2, Sigma, 10 ml ml 1) and
protease inhibitors (phenylmethylsulphonyl ﬂuoride in ethanol or protease
inhibitor cocktail, Sigma). Proteins were puriﬁed by centrifugation at 15,000g at
4 C for 20min and then quantiﬁed using bicinchoninic acid assay kit (Thermo
Fisher Scientiﬁc) and resolved on 7.5% Bis-Tris polyacrylamide gels, before being
transferred onto polyvinylidene ﬂuoride membranes via electroblotting. Blots were
probed with primary antibody overnight followed by horseradish peroxidise
(HRP)-conjugated secondary antibodies before being developed via enhanced
chemiluminescent substrate and exposure onto CL-XPosure ﬁlm (Thermo Fisher
Scientiﬁc). Molecular weight markers (Thermo Fisher Scientiﬁc 11832124 or New
England BioLab #7712) were run alongside all samples and values are as indicated
in both the main and uncropped scans (Supplementary Fig. 7).
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Co-immunoprecipitation of Nedd4L with Smad2. Cells were harvested in HEPES
lysis buffer (40mM HEPES pH 7.4, 10mM EDTA and 10% glycerol) supplemented
with phosphatase and protease inhibitors as per immunoblotting. Cell lysis was
induced mechanically by repeatedly passing lysate through a 23-G needle on ice.
Protein within lysates were puriﬁed by centrifugation at 13,000g at 4 C for 10min
and quantiﬁed, with 1mg used in the subsequent immunoprecipitation with Smad2
antibody for 90min at 4 C with rotation. Immunocomplexes were isolated with
the lysates using Protein-G conjugated Dynabeads (Life Technologies) through a
further 1 h incubation under the same conditions. Beads were then washed 3 times
with cold HEPES lysis buffer to remove nonspeciﬁc binding prior to protein elution
with 2 Laemmli buffer. Elutes were subjected to immunoblotting and the
co-immunoprecipitation assessed using relevant primary antibodies.
Smad2 ubiquitination assay. Cells were harvested in non-denaturing lysis buffer
(20mM Tris-HCl, pH 7.5, 150mM NaCl, 1mM EDTA, pH 8.0, 1mM EGTA,
pH 8.0 and 0.5% Nonidet-P40) supplemented with phosphatase and protease
inhibitors as per immunoblotting. Lysates were additionally supplemented with
2 mM ubiquitin aldehyde (Boston Biochem) to prevent the action of deubiquiti-
nating enzymes. Protein within lysates were puriﬁed and quantiﬁed, with 1mg used
in the subsequent immunoprecipitation with Smad2 antibody for 90min at 4 C
with rotation. Immunocomplexes were isolated from the lysates using Protein-G
conjugated Dynabeads through a further 1 h incubation under the same conditions.
Beads were then washed 3 times with cold non-denaturing lysis buffer to remove
nonspeciﬁc binding prior to protein elution with 2 Laemmli buffer. Elutes were
subjected to immunoblotting and the degree of ubiquitination was assessed using
an anti-ubiquitin antibody.
Generation of recombinant GST-Flag-Smad2/Smad2-T220V. pGEX-6p2
vectors containing Flag-Smad2/Smad2-T220V cDNAs were transformed into
BL-21 E. coli strain. Upon ampicillin selection, single colonies were used to
inoculate overnight cultures, which were then subsequently used to inoculate new
cultures the following day. Expression of GST-Flag-Smad2/Smad2-T220V was
induced in these cultures using 0.1M isopropyl b-D-1-thiogalactopyranoside
(Sigma) once they reached mid-log phase growth (OD550–600B0.6–1.0). Proteins
were harvested via centrifugation and sonication, followed by immunoprecipitation
with glutathione-conjugated magnetic beads (Thermo Fisher Scientiﬁc).
Recombinant proteins were eluted from the beads in 50mM Tris-HCl containing
10mM reduced glutathione. Proteins were then taken for immunoblotting with the
relevant antibodies to check for successful expression and then used as substrate for
subsequent kinase assays.
Akt/Erk2 kinase assay. HEK293T or PC3 cells were harvested using non-
denaturing lysis buffer (as per the Smad2 ubiquitination assay) to retain kinase
activity and supplemented with phosphatase and protease inhibitors as per
immunoblotting. Active Akt was immunoprecipitated using anti-pAkt (S473)
antibody and was tested for kinase activity via incubation with recombinant
GST-GSK3a/b fusion protein (NEB) as a substrate in kinase assay buffer
(25mM Tris-HCl, pH 7.5, 5mM b-glycerophosphate, 2mM DTT, 10mM MgCl2
and 200mM ATP) for 40min at 30 C. Kinase assay was repeated using GST-Flag-
Smad2/Smad2-T220V as substrate and phosphorylation of the linker region was
analysed via immunoblotting with the appropriate primary antibody. As a positive
control, GST-Flag-Smad2/Smad2-T220V proteins were incubated with Erk2 kinase
(NEB) in the supplied buffer supplemented with 200mM ATP and assessed for
phosphorylation via immunoblotting.
mTORC2 kinase assay. The assay was carried out using previously described
methods46 with the following modiﬁcations. HEK293T or PC3 cells were harvested
in mTORC lysis buffer (40mM HEPES pH 7.5, 120mM NaCl, 1mM EDTA,
10mM Na4P2O7, 50mM NaF and 0.5% Nonidet-P40) supplemented with
phosphatase and protease inhibitors as per immunoblotting. Cells were gently lysed
with rotation for 20min at 4 C after which 1mg of total protein was used in the
subsequent immunoprecipitation with Rictor antibody to selectively isolate
mTORC2 over mTORC1. Immunoprecipitated complexes were washed 3 times
with mTORC lysis buffer followed by washing with mTOR kinase assay buffer
(25mM HEPES, 100mM potassium acetate, 1mM MgCl2 and 500mM ATP)
twice to remove residual detergent. mTORC2 complexes were incubated with
l-phosphatase-treated His6-tagged-Akt1 (Millipore) protein or GST-Flag-Smad2/
Smad2-T220V recombinant proteins in mTORC kinase assay buffer for 40min at
37 C. Reactions were stopped upon the addition of 2 Laemmli buffer, and the
phosphorylation on Akt-S473 or SmadT220 residues was assessed by
immunoblotting with the appropriate primary antibodies.
Luciferase assay. hESCs were split 1:6 into 12-well plates using the accutase/
ROCKi method as above and allowed to reach 70–80% conﬂuence prior to
transfection. Both ﬁreﬂy pGL3-CAGA12-luc and renilla pRL-T7-renilla (Promega)
plasmids were transfected at a ratio of 10:1 using Lipofectamine 2000 following the
manufacturer’s protocol. Forty-two hours post transfection, hESCs were differ-
entiated for 6 h, harvested using accutase and dispensed into a 96-well luminometer
plate. Luciferase assay was performed using the Dual-Glo luciferase assay
kit (Promega) following the accompanying protocol. Both ﬁreﬂy and renilla
luminescence was recorded using a Victor II luminometer (Perkin Elmer). Fireﬂy
luminescence readings were normalized with corresponding renilla luminescence
readings to give representative luciferase expression values that are independent of
transfection efﬁciency and cell number. Data presented are mean±s.d. from three
independent transfection experiments.
References
1. Massague, J. & Wotton, D. Transcriptional control by the TGF-beta/Smad
signaling system. EMBO J. 19, 1745–1754 (2000).
2. Schmierer, B. & Hill, C. S. TGFbeta-SMAD signal transduction: molecular
speciﬁcity and functional ﬂexibility. Nat. Rev. Mol. Cell Biol. 8, 970–982 (2007).
3. Guo, X. & Wang, X. F. Signaling cross-talk between TGF-beta/BMP and other
pathways. Cell Res. 19, 71–88 (2009).
4. Feng, X. H. & Derynck, R. Speciﬁcity and versatility in tgf-beta signaling
through Smads. Annu. Rev. Cell Dev. Biol. 21, 659–693 (2005).
5. Massague, J. TGFbeta signalling in context. Nat. Rev. Mol. Cell Biol. 13,
616–630 (2012).
6. Ross, S. & Hill, C. S. How the Smads regulate transcription. Int. J. Biochem. Cell
Biol. 40, 383–408 (2008).
7. Chen, R. H., Su, Y. H., Chuang, R. L. & Chang, T. Y. Suppression of
transforming growth factor-beta-induced apoptosis through a
phosphatidylinositol 3-kinase/Akt-dependent pathway. Oncogene 17,
1959–1968 (1998).
8. Conery, A. R. et al. Akt interacts directly with Smad3 to regulate the sensitivity
to TGF-beta induced apoptosis. Nat. Cell Biol. 6, 366–372 (2004).
9. Remy, I., Montmarquette, A. & Michnick, S. W. PKB/Akt modulates TGF-beta
signalling through a direct interaction with Smad3. Nat. Cell Biol. 6, 358–365
(2004).
10. Song, K., Wang, H., Krebs, T. L. & Danielpour, D. Novel roles of Akt and
mTOR in suppressing TGF-beta/ALK5-mediated Smad3 activation. EMBO J.
25, 58–69 (2006).
11. D’Amour, K. A. et al. Efﬁcient differentiation of human embryonic stem cells to
deﬁnitive endoderm. Nat. Biotechnol. 23, 1534–1541 (2005).
12. Hay, D. C. et al. Efﬁcient differentiation of hepatocytes from human embryonic
stem cells exhibiting markers recapitulating liver development in vivo. Stem
Cells 26, 894–902 (2008).
13. McLean, A. B. et al. Activin a efﬁciently speciﬁes deﬁnitive endoderm from
human embryonic stem cells only when phosphatidylinositol 3-kinase signaling
is suppressed. Stem Cells 25, 29–38 (2007).
14. Singh, A. M. et al. Signaling network crosstalk in human pluripotent cells: a
Smad2/3-regulated switch that controls the balance between self-renewal and
differentiation. Cell Stem Cell 10, 312–326 (2012).
15. Chen, Y. G., Li, Z. & Wang, X. F. Where PI3K/Akt meets Smads: the crosstalk
determines human embryonic stem cell fate. Cell Stem Cell 10, 231–232 (2012).
16. Kubo, A. et al. Development of deﬁnitive endoderm from embryonic stem cells
in culture. Development 131, 1651–1662 (2004).
17. Teo, A. K. et al. Pluripotency factors regulate deﬁnitive endoderm speciﬁcation
through eomesodermin. Genes Dev. 25, 238–250 (2011).
18. Brown, S. et al. Activin/Nodal signaling controls divergent transcriptional
networks in human embryonic stem cells and in endoderm progenitors. Stem
Cells 29, 1176–1185 (2011).
19. Lin, X. et al. PPM1A functions as a Smad phosphatase to terminate TGFbeta
signaling. Cell 125, 915–928 (2006).
20. Shukla, A. et al. TGF-beta signalling is regulated by Schnurri-2-dependent
nuclear translocation of CLIC4 and consequent stabilization of phospho-Smad2
and 3. Nat. Cell Biol. 11, 777–784 (2009).
21. Bruce, D. L., Macartney, T., Yong, W., Shou, W. & Sapkota, G. P. Protein
phosphatase 5 modulates SMAD3 function in the transforming growth
factor-beta pathway. Cell Signal. 24, 1999–2006 (2012).
22. Lo, R. S. & Massague, J. Ubiquitin-dependent degradation of TGF-beta-
activated smad2. Nat. Cell Biol. 1, 472–478 (1999).
23. Gao, S. et al. Ubiquitin ligase Nedd4L targets activated Smad2/3 to limit
TGF-beta signaling. Mol. Cell 36, 457–468 (2009).
24. Alarcon, C. et al. Nuclear CDKs drive Smad transcriptional activation and
turnover in BMP and TGF-beta pathways. Cell 139, 757–769 (2009).
25. Kamaraju, A. K. & Roberts, A. B. Role of Rho/ROCK and p38 MAP kinase
pathways in transforming growth factor-beta-mediated Smad-dependent
growth inhibition of human breast carcinoma cells in vivo. J. Biol. Chem. 280,
1024–1036 (2005).
26. Kretzschmar, M., Doody, J., Timokhina, I. & Massague, J. A mechanism of
repression of TGFbeta/ Smad signaling by oncogenic Ras. Genes Dev. 13,
804–816 (1999).
27. Matsuura, I. et al. Cyclin-dependent kinases regulate the antiproliferative
function of Smads. Nature 430, 226–231 (2004).
28. Yamagata, H. et al. Acceleration of Smad2 and Smad3 phosphorylation via
c-Jun NH(2)-terminal kinase during human colorectal carcinogenesis. Cancer
Res. 65, 157–165 (2005).
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms8212 ARTICLE
NATURE COMMUNICATIONS | 6:7212 | DOI: 10.1038/ncomms8212 | www.nature.com/naturecommunications 11
& 2015 Macmillan Publishers Limited. All rights reserved.
29. Grimm, O. H. & Gurdon, J. B. Nuclear exclusion of Smad2 is a mechanism
leading to loss of competence. Nat. Cell Biol. 4, 519–522 (2002).
30. Wrighton, K. H., Lin, X. & Feng, X. H. Phospho-control of TGF-beta
superfamily signaling. Cell Res. 19, 8–20 (2009).
31. Lamming, D. W. & Sabatini, D. M. A central role for mTOR in lipid
homeostasis. Cell Metab. 18, 465–469 (2013).
32. Sarbassov, D. D. et al. Prolonged rapamycin treatment inhibits mTORC2
assembly and Akt/PKB. Mol. Cell 22, 159–168 (2006).
33. Shiota, C., Woo, J. T., Lindner, J., Shelton, K. D. & Magnuson, M. A.
Multiallelic disruption of the rictor gene in mice reveals that mTOR complex 2
is essential for fetal growth and viability. Dev. Cell 11, 583–589 (2006).
34. Garcia-Martinez, J. M. & Alessi, D. R. mTOR complex 2 (mTORC2)
controls hydrophobic motif phosphorylation and activation of serum- and
glucocorticoid-induced protein kinase 1 (SGK1). Biochem. J. 416, 375–385
(2008).
35. Heikamp, E. B. et al. The AGC kinase SGK1 regulates TH1 and TH2
differentiation downstream of the mTORC2 complex. Nat. Immunol. 15,
457–464 (2014).
36. Derynck, R. & Zhang, Y. E. Smad-dependent and Smad-independent pathways
in TGF-beta family signalling. Nature 425, 577–584 (2003).
37. Inman, G. J., Nicolas, F. J. & Hill, C. S. Nucleocytoplasmic shuttling of Smads 2,
3, and 4 permits sensing of TGF-beta receptor activity. Mol. Cell 10, 283–294
(2002).
38. Zhou, J. et al. mTOR supports long-term self-renewal and suppresses
mesoderm and endoderm activities of human embryonic stem cells. Proc. Natl
Acad. Sci. USA 106, 7840–7845 (2009).
39. Zinzalla, V., Stracka, D., Oppliger, W. & Hall, M. N. Activation of mTORC2 by
association with the ribosome. Cell 144, 757–768 (2011).
40. Oh, W. J. et al. mTORC2 can associate with ribosomes to promote
cotranslational phosphorylation and stability of nascent Akt polypeptide.
EMBO J. 29, 3939–3951 (2010).
41. Gerrard, L., Zhao, D., Clark, A. J. & Cui, W. Stably transfected human
embryonic stem cell clones express OCT4-speciﬁc green ﬂuorescent protein
and maintain self-renewal and pluripotency. Stem Cells 23, 124–133 (2005).
42. Hata, A., Lo, R. S., Wotton, D., Lagna, G. & Massague, J. Mutations increasing
autoinhibition inactivate tumour suppressors Smad2 and Smad4. Nature 388,
82–87 (1997).
43. Ramaswamy, S. et al. Regulation of G1 progression by the PTEN tumor
suppressor protein is linked to inhibition of the phosphatidylinositol 3-kinase/
Akt pathway. Proc. Natl Acad. Sci. USA 96, 2110–2115 (1999).
44. Sarbassov, D. D. et al. Rictor, a novel binding partner of mTOR, deﬁnes a
rapamycin-insensitive and raptor-independent pathway that regulates the
cytoskeleton. Curr. Biol. 14, 1296–1302 (2004).
45. Ovando-Roche, P., Yu, J. S., Testori, S., Ho, C. & Cui, W. TRF2-mediated
stabilization of hREST4 is critical for the differentiation and maintenance of
neural progenitors. Stem Cells 32, 2111–2122 (2014).
46. Sarbassov, D. D., Guertin, D. A., Ali, S. M. & Sabatini, D. M. Phosphorylation
and regulation of Akt/PKB by the rictor-mTOR complex. Science 307,
1098–1101 (2005).
47. Szulc, J., Wiznerowicz, M., Sauvain, M. O., Trono, D. & Aebischer, P. A
versatile tool for conditional gene expression and knockdown. Nat. Methods 3,
109–116 (2006).
48. Watanabe, K. et al. A ROCK inhibitor permits survival of dissociated human
embryonic stem cells. Nat. Biotechnol. 25, 681–686 (2007).
Acknowledgements
We thank Professor M.A. Magnuson, VUMC, Tennessee, for kindly providing rictor
null MEFs. We also thank our colleagues here at Imperial College London: Professor
V. Episkopou for the pGL3-CAGA12-luc construct; Professor E. Lam for the p70S6K
antibodies, Dr R. Kypta for PC3 cells; Professors V. Episkopou, M. Parker and
Dr R. Kypta for their helpful discussions. The work was supported by UK MRC and
Genesis Research Trust. T.S.R. was supported by a studentship from University of
Malaya/Ministry of Higher Education, Malaysia.
Author contributions
J.S.L.Y. and W.C. conceived the study and designed experiments. T.S.R. and J.S.L.Y.
performed hESC differentiation experiments and analysis. N.M. and R.C. generated
mutant Smad2 construct and recombinant Smad2 protein. M.K.H. characterized the
response of PC3 cells to PI3K/TGF-b. J.S.L.Y. and S.-K.W. analysed the molecular
mechanisms between Smad2/3 and Nedd4L, Akt and mTORC2. W.C. and J.S.L.Y. wrote
the manuscript.
Additional information
Supplementary Information accompanies this paper at http://www.nature.com/
naturecommunications
Competing ﬁnancial interests: The authors declare no competing ﬁnancial interests.
Reprints and permission information is available online at http://npg.nature.com/
reprintsandpermissions/
How to cite this article: Yu, J. S. L. et al. PI3K/mTORC2 regulates TGF-b/Activin
signalling by modulating Smad2/3 activity via linker phosphorylation. Nat. Commun.
6:7212 doi: 10.1038/ncomms8212 (2015).
This work is licensed under a Creative Commons Attribution 4.0
International License. The images or other third party material in this
article are included in the article’s Creative Commons license, unless indicated otherwise
in the credit line; if the material is not included under the Creative Commons license,
users will need to obtain permission from the license holder to reproduce the material.
To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms8212
12 NATURE COMMUNICATIONS | 6:7212 | DOI: 10.1038/ncomms8212 | www.nature.com/naturecommunications
& 2015 Macmillan Publishers Limited. All rights reserved.
